Alirocumab and Evolocumab are:
PCSK - 9 expressed over many tissues which inhibits metabolism of LDL - receptors. Drugs like Alirocumab & Evolocumab inhibit PCSK - 9 and increased LDL - receptor turnover. Thus they decrease the levels of LDL.
NPGL1 inhibitors
Microsomal transport protein inhibitors
PCSK - 9 inhibitors
Lipoprotein lipase inhibitors